The Pentalafen®/Heliance® combination therapy developed by Hemerion is designed to enhance the treatment of glioblastoma, the most prevalent brain cancer. This solution has already reached a significant level of clinical advancement and has recently been awarded a grant under the France 2030 investment plan, which will support its transition to the industrial and commercial phase.
France 2030, with a budget of €54 billion, is a significant investment plan supported by the French government, dedicated to supporting innovative technologies. Among its priorities are the fight against cancer and the industrialization of start-up innovations.
The plan provides Hemerion with funding for a significant portion of its combined therapy market-access program, estimated at €1 million in total.
France Relance’s support is provided in the form of a grant and a repayable advance. This further demonstrates the confidence placed in Hemerion’s development plan by the French government, the Hauts-de-France region, and BPI, the sponsors of France 2030.
Facilitating the adoption of the solution by neurosurgeons
The France Relance plan will finance the R&D program focusing on the overall ergonomics of the Heliance® illumination platform. This includes easier and faster assembly, Plug & Play operation, and other improvements. The goal is to accelerate the adoption of the technology by neurosurgical teams through greater ease of use in the operating theater.
These enhancements will be integrated into the next industrial pre-production run, in advance of the therapy’s international commercial launch.
Preparing for the international industrial and commercial launch
The investment will also facilitate the CE marking of the Heliance® platform and ISO 13485 certification of the company, two essential steps for marketing the therapy to healthcare establishments in the European Economic Area (EEA).